Tuberculosis Trial, Recruiting NCT06439810 Sponsor: Chinese University of Hong Kong Condition: Tuberculosis
Back to Tuberculosis

Tuberculosis Trial, Recruiting

NCT06439810
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have recently developed a new build-up of fluid around the lung and are already scheduled to have a procedure to drain that fluid
  • People who are 18 years of age or older
  • People who are able to understand and agree to participate by signing a consent form

Who may not be able to join:

  • People who have previously had tuberculosis (TB) affecting the lining around the lung on the same side, or who have had any treatments injected into that same pleural space (such as talc or clot-dissolving medicines) — note that people with a history of TB in other parts of the body who have completed their TB treatment may still be considered eligible (confirm with trial site)
  • People who have previously had surgery involving the same side of the chest, including procedures to remove the lung lining, seal the pleural space, or remove part of the lung
  • People who have been taking two or more TB medications at the same time for more than 7 days in a row within the past 3 months — the medications this refers to include isoniazid, rifampicin, pyrazinamide, ethambutol, amikacin, streptomycin, levofloxacin, moxifloxacin, and linezolid
  • People who have not been able to provide consent to participate in the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ka Pang Chan, MBChB, Prince of Wales Hospital, Shatin, Hong Kong

Phone: 35052211

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 April 2025
Est. completion
31 December 2026

Where this trial is recruiting

Hong Kong

Primary endpoints

diagnostic accuracy of the new MTB cfDNA assay

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov